PE20121524A1 - Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos - Google Patents
Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticosInfo
- Publication number
- PE20121524A1 PE20121524A1 PE2012001082A PE2012001082A PE20121524A1 PE 20121524 A1 PE20121524 A1 PE 20121524A1 PE 2012001082 A PE2012001082 A PE 2012001082A PE 2012001082 A PE2012001082 A PE 2012001082A PE 20121524 A1 PE20121524 A1 PE 20121524A1
- Authority
- PE
- Peru
- Prior art keywords
- therapeutic agents
- combinations
- compounds including
- hiv integrase
- including inhibitors
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 108010002459 HIV Integrase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 abstract 1
- 229960004748 abacavir Drugs 0.000 abstract 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 abstract 1
- 229960003804 efavirenz Drugs 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229960004525 lopinavir Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UNA COMBINACION QUE COMPRENDE (4R,12aS)-N-[2,4-FLUORO-FENIL)-METIL]-3,4,6,8,12,12a-HEXAHIDRO-7-HIDROXI-4-METIL-6,8-DIOXO-2H-PIRIDO-[1',2':4,5]-PIRAZINO-[2,1-b][1,3]-OXAZIN-9-CARBOXAMIDA CON UNO O MAS AGENTES TERAPEUTICOS TAL COMO ABACAVIR, EFAVIRENZ O LOPINAVIR, Y ADICIONALMENTE LAMIVUDINA. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHA COMBINACION ES UTIL EN LA PREVENCION Y/O TRATAMIENTO DE LA INFECCION POR VIH Y EN EL TRATAMIENTO DE SIDA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29858910P | 2010-01-27 | 2010-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121524A1 true PE20121524A1 (es) | 2012-12-03 |
Family
ID=44319704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000261A PE20160180A1 (es) | 2010-01-27 | 2011-01-24 | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos. |
| PE2012001082A PE20121524A1 (es) | 2010-01-27 | 2011-01-24 | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000261A PE20160180A1 (es) | 2010-01-27 | 2011-01-24 | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos. |
Country Status (45)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2932970T3 (pl) | 2010-01-27 | 2018-08-31 | Viiv Healthcare Co | Terapia antywirusowa |
| EP2911674A1 (en) | 2012-10-23 | 2015-09-02 | Cipla Limited | Pharmaceutical antiretroviral composition |
| DK3608325T3 (da) | 2012-12-21 | 2022-08-22 | Gilead Sciences Inc | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse |
| US9480655B2 (en) | 2013-02-18 | 2016-11-01 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of dolutegravir |
| EP2767272A1 (en) * | 2013-02-18 | 2014-08-20 | Ratiopharm GmbH | Solid pharmaceutical dosage form of dolutegravir |
| NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
| EP3019503B1 (en) | 2013-07-12 | 2017-09-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
| AU2014324829B2 (en) | 2013-09-27 | 2017-09-07 | Merck Sharp & Dohme Corp. | Substituted Quinolizine Derivatives useful as HIV integrase inhibitors |
| WO2015140569A1 (en) | 2014-03-20 | 2015-09-24 | Cipla Limited | Pharmaceutical composition |
| JP6768522B2 (ja) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| EP3177629B1 (en) | 2014-07-29 | 2020-01-29 | LEK Pharmaceuticals d.d. | Novel hydrates of dolutegravir sodium |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016161382A1 (en) | 2015-04-02 | 2016-10-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2017029226A1 (en) | 2015-08-14 | 2017-02-23 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
| WO2017205585A1 (en) * | 2016-05-27 | 2017-11-30 | Viiv Healthcare Company | Combinations and uses treatments thereof |
| WO2018028841A1 (en) * | 2016-08-12 | 2018-02-15 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
| WO2018042332A1 (en) * | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | COMBINATION THERAPY |
| EP3654981A4 (en) * | 2017-07-21 | 2021-04-21 | VIIV Healthcare Company | DIETS AND PREPARATIONS FOR THE TREATMENT OF HIV INFECTIONS AND AIDS |
| CN111107850A (zh) | 2017-07-21 | 2020-05-05 | Viiv保健公司 | 用于治疗hib感染和aids的方案 |
| IL273704B2 (en) * | 2017-10-13 | 2024-06-01 | Viiv Healthcare Co | Bi-layer pharmaceutical tablet formulations comprising lamivudine and dolutegravir sodium for use in treating hiv |
| CN119462659A (zh) | 2019-03-22 | 2025-02-18 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
| US20230270677A1 (en) * | 2020-01-09 | 2023-08-31 | University Of Washington | Long-acting therapeutic agent combinations and methods thereof |
| AU2021225809B2 (en) | 2020-02-24 | 2023-08-24 | Gilead Sciences, Inc. | Tetracyclic compounds for treating HIV infection |
| CA3202957A1 (en) | 2021-01-19 | 2022-07-28 | Hang CHU | Substituted pyridotriazine compounds and uses thereof |
| AU2023225805A1 (en) * | 2022-02-28 | 2024-10-17 | Jericho Sciences, Llc | Methods for viral infections |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US7119202B1 (en) | 1989-02-08 | 2006-10-10 | Glaxo Wellcome Inc. | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| ZA923640B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| GB9204015D0 (en) | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
| US5663169A (en) | 1992-08-07 | 1997-09-02 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| IL106507A (en) | 1992-08-07 | 1997-11-20 | Merck & Co Inc | Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type |
| GB9402161D0 (en) | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
| IL113432A (en) | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
| UA49803C2 (uk) | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| BR9709939A (pt) * | 1996-06-25 | 1999-08-10 | Glaxo Group Ltd | Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5965729A (en) | 1997-02-05 | 1999-10-12 | Merck & Co., Inc. | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
| GB9709945D0 (en) | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| GB9717928D0 (en) | 1997-08-22 | 1997-10-29 | Glaxo Group Ltd | Process for the enatioselective hydrolysis of n-derivatised lactams |
| GB9721780D0 (en) | 1997-10-14 | 1997-12-10 | Glaxo Group Ltd | Process for the synthesis of chloropurine intermediates |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6087383A (en) | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| GB9805898D0 (en) | 1998-03-20 | 1998-05-13 | Glaxo Group Ltd | Process for the sythesis of hiv protease inhibitors |
| WO1999048371A1 (en) | 1998-03-27 | 1999-09-30 | The Regents Of The University Of California | Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors |
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| WO2001054625A1 (en) | 2000-01-31 | 2001-08-02 | Cook Biotech Incorporated | Stent valves and uses of same |
| EE05400B1 (et) | 2001-04-10 | 2011-04-15 | Pfizer Inc. | Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US7638522B2 (en) * | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
| TW200403061A (en) * | 2002-06-04 | 2004-03-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| JP2005533870A (ja) * | 2002-06-27 | 2005-11-10 | メディヴィル・アクチボラグ | アバカビールおよびアロブジンの相乗的相互作用 |
| DK1583542T3 (da) * | 2003-01-14 | 2008-09-22 | Gilead Sciences Inc | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| BRPI0507628A (pt) * | 2004-02-11 | 2007-07-03 | Smithkline Beecham Corp | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto |
| JP4285353B2 (ja) | 2004-03-05 | 2009-06-24 | 清水建設株式会社 | 化学物質放散度評価方法 |
| PL1742642T3 (pl) * | 2004-04-14 | 2009-06-30 | Gilead Sciences Inc | Analogi fosfonianowe związków inhibitorów integrazy HIV |
| EP3287130A1 (en) | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| ATE495747T1 (de) | 2004-08-23 | 2011-02-15 | Teva Pharma | Kristalline form des ibandronat-natriums und herstellungsverfahren dafür |
| PL1632232T6 (pl) | 2004-09-02 | 2022-06-27 | Janssen Pharmaceutica Nv | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu |
| PT1799696E (pt) | 2004-09-17 | 2009-02-16 | Idenix Pharmaceuticals Inc | Fosfoindoles como inibidores de hiv |
| US7250421B2 (en) | 2005-01-31 | 2007-07-31 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase |
| JP2008531716A (ja) | 2005-03-04 | 2008-08-14 | スミスクライン ビーチャム コーポレーション | 化合物 |
| UA96568C2 (en) * | 2005-04-28 | 2011-11-25 | Глаксосмиткляйн Ллк | Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor |
| SI3284520T1 (sl) | 2005-04-28 | 2019-10-30 | Viiv Healthcare Co | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
| US20080280849A1 (en) | 2005-06-01 | 2008-11-13 | Herve Leh | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents |
| EA018544B1 (ru) * | 2005-12-30 | 2013-08-30 | Джилид Сайэнс, Инк. | Способ лечения ретровирусной инфекции |
| UA108605C2 (uk) * | 2005-12-30 | 2015-05-25 | Спосіб покращення фармакокінетики інгібіторів інтегрази віл | |
| NZ569347A (en) * | 2006-01-20 | 2011-07-29 | Tibotec Pharm Ltd | Long term treatment of HIV-infection with 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| US20080039428A1 (en) | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
| NZ573887A (en) | 2006-07-21 | 2012-02-24 | Gilead Sciences Inc | Antiviral protease inhibitors |
| WO2008042240A2 (en) | 2006-09-29 | 2008-04-10 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as hiv inhibitors |
| TW200835693A (en) | 2007-02-23 | 2008-09-01 | Auspex Pharmaceuticals Inc | Preparation and utility of non-nucleoside reverse transcriptase inhibitors |
| CN101679325B (zh) | 2007-02-23 | 2013-08-28 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
| KR20100041798A (ko) | 2007-06-29 | 2010-04-22 | 한국화학연구원 | 신규 ｈｉｖ 역전사효소 억제제 |
| US8334295B2 (en) | 2007-06-29 | 2012-12-18 | Korea Research Institute Of Chemical Technology | Pyrimidine derivatives as HIV reverse transcriptase inhibitors |
| KR20100040896A (ko) | 2007-07-06 | 2010-04-21 | 길리애드 사이언시즈, 인코포레이티드 | 치료제의 약동학적 특성의 조절제 |
| JP5701057B2 (ja) * | 2007-07-12 | 2015-04-15 | ヤンセン サイエンシズ アイルランド ユーシー | （ｅ）４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの結晶形 |
| WO2009058923A1 (en) | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| JP2011502998A (ja) | 2007-11-01 | 2011-01-27 | ザ ユーエイビー リサーチ ファウンデイション | ウイルス感染の治療および予防 |
| US8108055B2 (en) | 2007-12-28 | 2012-01-31 | Larry Wong | Method, system and apparatus for controlling an electrical device |
| JP2011508748A (ja) * | 2008-01-03 | 2011-03-17 | バイロケム ファーマ インコーポレイテッド | 新規のルパン誘導体 |
| EP2240504A1 (en) | 2008-01-03 | 2010-10-20 | Virochem Pharma Inc. | Novel c-21-keto lupane derivatives preparation and use thereof |
| CA2710679A1 (en) | 2008-01-04 | 2009-07-16 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| WO2009148600A2 (en) * | 2008-06-06 | 2009-12-10 | Concert Pharmaceuticals, Inc. | Deuterated lysine-based compounds |
| DK2320908T3 (en) * | 2008-07-25 | 2014-03-10 | Viiv Healthcare Co | DOLUTEGRAVIR prodrugs |
| PT3617194T (pt) | 2008-12-11 | 2023-11-27 | Shionogi & Co | Processos e intermediários para inibidores carbamoilpiridona da integrase do vih |
| SG171308A1 (en) * | 2008-12-11 | 2011-07-28 | Shionogi & Co | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| PL2932970T3 (pl) | 2010-01-27 | 2018-08-31 | Viiv Healthcare Co | Terapia antywirusowa |
| GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| WO2011160024A2 (en) | 2010-06-17 | 2011-12-22 | Fuzians Biomedicals, Inc. | Compounds useful as antiviral agents, compositions, and methods of use |
| JP2014509654A (ja) | 2011-04-01 | 2014-04-21 | ザ メディシンズ カンパニー | 脳卒中損傷の低減に使用するための短時間作用型ジヒドロピリジン（クレビジピン） |
-
2011
- 2011-01-24 PL PL15164931T patent/PL2932970T3/pl unknown
- 2011-01-24 NZ NZ601319A patent/NZ601319A/en unknown
- 2011-01-24 EP EP11737484.3A patent/EP2531027B1/en not_active Revoked
- 2011-01-24 SG SG10201509476RA patent/SG10201509476RA/en unknown
- 2011-01-24 FI FIEP19151897.6T patent/FI3494972T3/fi active
- 2011-01-24 WO PCT/US2011/022219 patent/WO2011094150A1/en active Application Filing
- 2011-01-24 DK DK15164931.6T patent/DK2932970T3/en active
- 2011-01-24 CN CN201510619148.8A patent/CN105311033B/zh active Active
- 2011-01-24 EP EP15164931.6A patent/EP2932970B1/en not_active Revoked
- 2011-01-24 PT PT191518976T patent/PT3494972T/pt unknown
- 2011-01-24 EP EP19151897.6A patent/EP3494972B1/en active Active
- 2011-01-24 MY MYPI2019000564A patent/MY202778A/en unknown
- 2011-01-24 PE PE2016000261A patent/PE20160180A1/es unknown
- 2011-01-24 NZ NZ627827A patent/NZ627827A/en unknown
- 2011-01-24 CA CA3060290A patent/CA3060290C/en active Active
- 2011-01-24 RS RS20181178A patent/RS57728B1/sr unknown
- 2011-01-24 MY MYPI2012003346A patent/MY188334A/en unknown
- 2011-01-24 RS RS20150462A patent/RS54123B1/en unknown
- 2011-01-24 HU HUE11737484A patent/HUE026849T2/en unknown
- 2011-01-24 DK DK16187411.0T patent/DK3127542T3/en active
- 2011-01-24 SM SM20180290T patent/SMT201800290T1/it unknown
- 2011-01-24 LT LTEP19151897.6T patent/LT3494972T/lt unknown
- 2011-01-24 MX MX2012008774A patent/MX2012008774A/es active IP Right Grant
- 2011-01-24 RS RS20240189A patent/RS65183B1/sr unknown
- 2011-01-24 ME MEP-2015-106A patent/ME02182B/me unknown
- 2011-01-24 ES ES15164931.6T patent/ES2670811T3/es active Active
- 2011-01-24 JP JP2012551213A patent/JP2013518107A/ja active Pending
- 2011-01-24 EA EA202190473A patent/EA202190473A3/ru unknown
- 2011-01-24 NO NO15164931A patent/NO2932970T3/no unknown
- 2011-01-24 HR HRP20240168TT patent/HRP20240168T1/hr unknown
- 2011-01-24 MX MX2014014687A patent/MX367938B/es unknown
- 2011-01-24 PT PT151649316T patent/PT2932970T/pt unknown
- 2011-01-24 EA EA201892277A patent/EA037601B1/ru active Protection Beyond IP Right Term
- 2011-01-24 ES ES16187411.0T patent/ES2688925T3/es active Active
- 2011-01-24 KR KR1020177017713A patent/KR20170078868A/ko not_active Ceased
- 2011-01-24 KR KR1020187018909A patent/KR101964923B1/ko active Active
- 2011-01-24 SM SM20180594T patent/SMT201800594T1/it unknown
- 2011-01-24 LT LTEP16187411.0T patent/LT3127542T/lt unknown
- 2011-01-24 PT PT117374843T patent/PT2531027E/pt unknown
- 2011-01-24 DK DK19151897.6T patent/DK3494972T3/da active
- 2011-01-24 SI SI201131492T patent/SI2932970T1/en unknown
- 2011-01-24 PH PH1/2012/501537A patent/PH12012501537A1/en unknown
- 2011-01-24 KR KR1020127022254A patent/KR101830715B1/ko active Active
- 2011-01-24 MA MA35145A patent/MA34002B1/fr unknown
- 2011-01-24 AU AU2011209788A patent/AU2011209788C1/en active Active
- 2011-01-24 CN CN201180015114.8A patent/CN102791129B/zh active Active
- 2011-01-24 EP EP16187411.0A patent/EP3127542B1/en active Active
- 2011-01-24 AP AP2012006445A patent/AP3551A/xx active
- 2011-01-24 PL PL19151897.6T patent/PL3494972T3/pl unknown
- 2011-01-24 BR BR112012018670-1A patent/BR112012018670A2/pt not_active Application Discontinuation
- 2011-01-24 ME MEP-2018-131A patent/ME03058B/me unknown
- 2011-01-24 RS RS20180667A patent/RS57323B1/sr unknown
- 2011-01-24 MX MX2014014689A patent/MX356891B/es unknown
- 2011-01-24 LT LTEP15164931.6T patent/LT2932970T/lt unknown
- 2011-01-24 EA EA201690872A patent/EA032868B1/ru active Protection Beyond IP Right Term
- 2011-01-24 MX MX2014014688A patent/MX367937B/es unknown
- 2011-01-24 SG SG10201707183TA patent/SG10201707183TA/en unknown
- 2011-01-24 ES ES11737484.3T patent/ES2543066T3/es active Active
- 2011-01-24 HU HUE16187411A patent/HUE040554T2/hu unknown
- 2011-01-24 SI SI201132101T patent/SI3494972T1/sl unknown
- 2011-01-24 CA CA2967453A patent/CA2967453C/en active Active
- 2011-01-24 EP EP18161536.0A patent/EP3351249A1/en not_active Withdrawn
- 2011-01-24 SI SI201130539T patent/SI2531027T1/sl unknown
- 2011-01-24 US US13/575,380 patent/US20120295898A1/en not_active Abandoned
- 2011-01-24 HU HUE15164931A patent/HUE037812T2/hu unknown
- 2011-01-24 PL PL11737484T patent/PL2531027T3/pl unknown
- 2011-01-24 NZ NZ627826A patent/NZ627826A/en unknown
- 2011-01-24 PE PE2012001082A patent/PE20121524A1/es active IP Right Grant
- 2011-01-24 CA CA3003988A patent/CA3003988C/en active Active
- 2011-01-24 SM SM20240063T patent/SMT202400063T1/it unknown
- 2011-01-24 EA EA201290583A patent/EA025176B1/ru active Protection Beyond IP Right Term
- 2011-01-24 EP EP23214771.0A patent/EP4316599A3/en active Pending
- 2011-01-24 TR TR2018/07704T patent/TR201807704T4/tr unknown
- 2011-01-24 SI SI201131593T patent/SI3127542T1/sl unknown
- 2011-01-24 PL PL16187411T patent/PL3127542T3/pl unknown
- 2011-01-24 UA UAA201209253A patent/UA105556C2/uk unknown
- 2011-01-24 CA CA2787691A patent/CA2787691C/en active Active
- 2011-01-24 NZ NZ627824A patent/NZ627824A/en unknown
- 2011-01-24 DK DK11737484.3T patent/DK2531027T3/en active
- 2011-01-24 KR KR1020167025050A patent/KR101883750B1/ko active Active
- 2011-01-24 ES ES19151897T patent/ES2969969T3/es active Active
- 2011-01-24 PT PT16187411T patent/PT3127542T/pt unknown
- 2011-01-24 HU HUE19151897A patent/HUE065569T2/hu unknown
- 2011-01-24 SG SG2012053492A patent/SG182614A1/en unknown
-
2012
- 2012-07-18 DO DO2012000205A patent/DOP2012000205A/es unknown
- 2012-07-18 IL IL221007A patent/IL221007A/en active IP Right Grant
- 2012-07-24 TN TNP2012000376A patent/TN2012000376A1/en unknown
- 2012-07-24 ZA ZA2012/05586A patent/ZA201205586B/en unknown
- 2012-07-26 CL CL2012002080A patent/CL2012002080A1/es unknown
- 2012-07-26 CO CO12125933A patent/CO6602152A2/es active IP Right Grant
- 2012-08-13 CR CR20120423A patent/CR20120423A/es unknown
- 2012-08-14 EC ECSP12012106 patent/ECSP12012106A/es unknown
-
2013
- 2013-06-06 HK HK13106716.5A patent/HK1179522A1/xx not_active IP Right Cessation
- 2013-06-06 HK HK18109751.0A patent/HK1250335A1/zh unknown
- 2013-06-06 HK HK15110408.8A patent/HK1209629A1/xx unknown
-
2015
- 2015-05-13 US US14/710,952 patent/US20150238496A1/en not_active Abandoned
- 2015-07-14 HR HRP20150770TT patent/HRP20150770T1/hr unknown
- 2015-07-17 CY CY20151100633T patent/CY1116509T1/el unknown
- 2015-07-24 SM SM201500177T patent/SMT201500177B/xx unknown
-
2016
- 2016-01-28 PH PH12016500195A patent/PH12016500195B1/en unknown
- 2016-01-29 JP JP2016015242A patent/JP2016145204A/ja active Pending
- 2016-03-18 US US15/073,728 patent/US20160199379A1/en not_active Abandoned
- 2016-04-18 IL IL245182A patent/IL245182B/en active IP Right Grant
- 2016-08-01 US US15/224,865 patent/US20160339033A1/en not_active Abandoned
- 2016-08-22 JP JP2016161610A patent/JP6268386B2/ja active Active
- 2016-12-01 US US15/366,442 patent/US10426780B2/en active Active
- 2016-12-01 US US15/366,566 patent/US20170119777A1/en not_active Abandoned
-
2017
- 2017-04-19 US US15/490,944 patent/US20170216284A1/en not_active Abandoned
- 2017-06-13 US US15/620,859 patent/US20170281636A1/en not_active Abandoned
- 2017-12-12 US US15/838,738 patent/US20180098992A1/en not_active Abandoned
-
2018
- 2018-01-31 IL IL257267A patent/IL257267B/en active IP Right Grant
- 2018-03-15 US US15/922,240 patent/US20180200254A1/en not_active Abandoned
- 2018-04-05 JP JP2018072861A patent/JP2018127473A/ja active Pending
- 2018-05-23 CY CY20181100548T patent/CY1120457T1/el unknown
- 2018-05-30 HR HRP20180855TT patent/HRP20180855T1/hr unknown
- 2018-09-26 HR HRP20181531TT patent/HRP20181531T1/hr unknown
- 2018-10-15 FR FR18C1043C patent/FR18C1043I2/fr active Active
- 2018-10-15 NO NO2018036C patent/NO2018036I1/no unknown
- 2018-10-16 CY CY2018029C patent/CY2018029I2/el unknown
- 2018-10-22 LT LTPA2018013C patent/LTC2932970I2/lt unknown
- 2018-10-23 CY CY181101087T patent/CY1121040T1/el unknown
- 2018-10-26 HU HUS1800042C patent/HUS1800042I1/hu unknown
- 2018-10-31 LU LU00090C patent/LUC00090I2/en unknown
- 2018-11-26 PH PH12018502489A patent/PH12018502489A1/en unknown
-
2019
- 2019-06-07 JP JP2019106635A patent/JP2019167371A/ja active Pending
- 2019-06-26 IL IL267658A patent/IL267658B/en active IP Right Grant
-
2020
- 2020-03-31 US US16/835,733 patent/US11234985B2/en active Active
-
2021
- 2021-02-26 JP JP2021030306A patent/JP2021091705A/ja active Pending
- 2021-04-01 IL IL281959A patent/IL281959B/en unknown
- 2021-07-14 DO DO2021000147A patent/DOP2021000147A/es unknown
- 2021-09-08 US US17/468,794 patent/US20210401850A1/en not_active Abandoned
-
2022
- 2022-03-03 JP JP2022032464A patent/JP2022071126A/ja active Pending
-
2023
- 2023-04-04 JP JP2023060638A patent/JP2023085431A/ja active Pending
-
2024
- 2024-05-31 FI FIC20240016C patent/FIC20240016I1/fi unknown
- 2024-06-03 HU HUS2400017C patent/HUS2400017I1/hu unknown
- 2024-06-06 FR FR24C1024C patent/FR24C1024I1/fr active Active
- 2024-10-01 US US18/903,013 patent/US20250017939A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121524A1 (es) | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos | |
| CO6460772A2 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| CL2008003405A1 (es) | Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih. | |
| UA114351C2 (uk) | Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування | |
| EP2493464A4 (en) | METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICRO-ORGANISMS | |
| GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| CL2008003406A1 (es) | Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih. | |
| EA201390198A1 (ru) | Гетероциклическое соединение | |
| MX2011009847A (es) | Agentes antihelminticos y su uso. | |
| PE20120713A1 (es) | Composiciones sublinguales de dexmedetomidina y metodos para su uso | |
| MY172303A (en) | Compositions and methods of use of phorbol esters | |
| BR112014015630A2 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas | |
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| EP2269611A3 (en) | EP2 and EP4 agonists as agents for the treatment of influenza A viral infection | |
| BR112012015967A2 (pt) | uso de compostos de fórmula geral (i) e composição farmacêutica | |
| BRPI1014902A2 (pt) | composto antagonista de p2x7r, sua composição e seus usos | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| CL2011002847A1 (es) | Uso de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmaceuticamente aceptable del mismo y un inhibidor de acetilcolinesterasa para preparar un medicamento util para mejorar la cognicion. | |
| BR112012017705A2 (pt) | derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase | |
| PE20121538A1 (es) | Combinaciones terapeuticas de teobromina y una antihistamina | |
| MA34946B1 (fr) | Nouvelles benzodioxolepipérazines | |
| CL2009000636A1 (es) | Compuestos derivados de 1-(1h-pirazol-3-il)-imidazolidin-4-ona sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de enfermedades retrovirales, tal como infeccion por vih. | |
| CL2012002743A1 (es) | Combinación que comprende maraviroc, un inhibidor de proteasa de vih-1 y un potenciador famacocinetico, uso en la preparacion de un medicamento util en el tratmiento de infeccion por vih. | |
| MX2020009070A (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |